The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design
نویسندگان
چکیده
Introduction We investigated the influence of different inclusion criteria for preclinical and prodromal Alzheimer's disease (AD) on changes in biomarkers and cognitive markers and on trial sample size estimates. Methods We selected 522 cognitively normal subjects and 872 subjects with mild cognitive impairment from the Alzheimer's Disease Neuroimaging Initiative study. Compared inclusion criteria were (1) preclinical or prodromal AD (amyloid marker abnormal); (2) preclinical or prodromal AD stage-1 (amyloid marker abnormal, injury marker normal); and (3) preclinical or prodromal AD stage-2 (amyloid and injury markers abnormal). Outcome measures were amyloid, neuronal injury, and cognitive markers. Results In both subjects with preclinical and prodromal AD stage-2, inclusion criteria resulted in the largest observed decline in brain volumetric measures on magnetic resonance imaging and cognitive markers. Discussion Inclusion criteria influence the observed rate of worsening in outcome measures. This has implications for trial design.
منابع مشابه
Advances in designs for Alzheimer's disease clinical trials.
There is an urgent need to identify new treatments for the rapidly growing population of people with Alzheimer's disease (AD). Innovations in clinical trial designs many help to reduce development time, provide more definitive answers regarding drug efficacy, and facilitate prioritizing compounds to be advanced to Phase III clinical trials. Standard designs compare drug and placebo changes from...
متن کاملDetermination of the Most Important Diagnostic Criteria for COVID-19: A Step forward to Design an Intelligent Clinical Decision Support System
Background & Objective: Since the clinical and epidemiologic characteristics of coronavirus disease 2019 (COVID-19) is not well known yet, investigating its origin, etiology, diagnostic criteria, clinical manifestations, risk factors, treatments, and other related aspects is extremely important. In this situation, clinical experts face many uncertainties to make decision about COVID-19 progn...
متن کاملReduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease.
OBJECTIVE Cortical thinning, previously identified during prodromal stages of Alzheimer's disease (AD), is a "candidate" biomarker implemented in AD clinical therapy trials. We investigated the effect of donepezil treatment on cortical thickness in mild cognitively impaired subjects with the amnestic syndrome of the hippocampal type, a prodromal at-risk group for progression to AD dementia. M...
متن کاملMRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults.
OBJECTIVE New preclinical Alzheimer disease (AD) diagnostic criteria have been developed using biomarkers in cognitively normal (CN) adults. We implemented these criteria using an MRI biomarker previously associated with AD dementia, testing the hypothesis that individuals at high risk for preclinical AD would be at elevated risk for cognitive decline. METHODS The Alzheimer's Disease Neuroima...
متن کاملThe Effect of Cognitive Rehabilitation on the Memory Improvement of Alzheimer\'s Disease Patients
Objectives: Alzheimer's is the most prevalent cognitive disturbance, with a high spread among the elderly. The current research aims to investigate the impact of cognitive rehabilitation on the memory improvement of Alzheimer's disease patients. Methods: The current research used a semi-experimental design with pre-test and post-test designs. The statistical population in Baghdad in 2021 inclu...
متن کامل